Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: Preparation of a genetically engineered anti-CEA single chain Fv antibody

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 968-976

  Mayer, A ^a   Chester, K A ^a   Bhatia, J ^a   Pedley, R B ^a   Read, D A ^a   Boxer, G M ^a   Begent, R H J ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Biotechnology; Control recommendations; Quality; Safety; Single chain Fv

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; MFE 23 HEXAHISTIDINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG PURITY; DRUG QUALITY; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; IMMUNOSCINTIGRAPHY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY;

BIOTECHNOLOGY; CARCINOEMBRYONIC ANTIGEN; CLINICAL TRIALS, PHASE I; DNA, RECOMBINANT; DRUG STABILITY; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOHISTOCHEMISTRY; PRACTICE GUIDELINES; QUALITY CONTROL;

EID: 0032101441     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00035-5     Document Type: Article

References (13)

1. Begent RHJ, Chester KA. Connors F, et al. Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for administration to patients with cancer in phase I trials. Eur J Cancer 1993, 29A, 13, 1907-1010.
2. Berthold W., Waiter J. Protein purification: aspects of processes for pharmaceutical products. Biologicals. 22:1994;135-150.
3. Chester KA, Begent RHJ, Robson L, et al. Phage libraries for generation of clinically useful antibodies. Lancet 1994, 343, 8895, 455-456.
4. Casey J.L., Keep P.A., Chester K.A., Robson L., Hawkins R.E., Begent R.H.J. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J Immunol Methods. 179:1995;105-116.
5. Begent RHJ, Verhaar MJ, Chester KA, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nature Med 1996, 2, 979-984.
6. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual. New York, Cold Spring Harbour Laboratory, 1982.
7. Verhaar MJ, Chester KA. Keep PA, et al. A single chain Fv derived from a filamentous phage library has distinct tumour targeting advantages over one derived from hybridoma. Int J Cancer 1995, 61, 497-501.
8. Pedley RB, Boden JA, Boden R, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996, 56, 3293-300.
9. Arrigo C., Koier I.J., McVie J.G., Marsoni S., Newlands E., Schwartsmann G. Minimal guidelines for the monitoring of early clinical trials (phase I-II) in Europe under CRC/EORTC/NCI joint agreement. Eur J Cancer. 28A:1992;1289-1292.
10. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York, The Society of Nuclear Medicine, 1991.
11. International commission on radiological protection. 1990 Recommendations of the International Commission on Radiological Protection. Oxford, ICRP publication 60, Pergamon Press, 1990.
12. The working party on clinical use of antibodies. Operation manual for control of production, preclinical toxicology and phase I trials of anti-tumour antibodies and drug antibody conjugates. Br J Cancer 1986, 54, 557-568.
13. 2 antibodies. Br J Cancer 1994, 70, 521-525.